VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2019 | IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line

A study of ibrutinib-rituximab plus short course R-HCVAD/R-MTX for previously untreated, young mantle cell lymphoma (MCL) patients was presented by M. Wang at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, his colleague Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the findings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter